GO
Loading...

FDA Cautious on Risks of Johnson & Johnson, Amgen Anemia Drug

U.S. Food and Drug Administration staffers on Tuesday expressed continued caution over the use of anemia drugs sold by Amgenand Johnson & Johnson

, according to an agency document released on Tuesday.

More data is needed on the risks with the drugs, which include Amgen's Aranesp and Epogen and J&J's Procrit, the agency staff said. Changes to the products' labeling may also be appropriate, they added.

The document was released ahead of an FDA advisory panel meeting on Thursday to discuss the risks of using the erythropoiesis-stimulating agents in cancer patients.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More

Don't Miss

U.S. Video

  • Mad Money's Jim Cramer breaks down the theme of stealth technology stocks. Cramer says companies that are using proprietary technology to invent entirely new markets and then dominate those markets, fall under that category.

  • Mad Money host Jim Cramer knows it can be difficult to stick with a stock that is going lower but says if you've done the homework, and the story isn't wildly off the rails, then stay long.

  • Mad Money host Jim Cramer, outlines the most common emotionally driven investor mistakes and expresses why it is important to not let skepticism run away with you.